Simulations Plus (SLP) Azione Prezzo
Simulations Plus Prezzo
Negli ultimi 19 anni Simulations Plus ha aumentato il fatturato del 14,7% all'anno, raggiungendo 79,18 Mio. USD. L'utile per azione è cresciuto del 15,0% all'anno negli ultimi 18 anni. Per Simulations Plus, il margine netto del -81,7% risulta in calo rispetto al 21,1% di alcuni anni fa. Al prezzo attuale il rendimento da dividendo è pari a circa il 0,97%. Il payout ratio è pari a circa il 37% degli utili. Il target di prezzo di consenso a 12 mesi per Simulations Plus è 18,50 USD, circa il 0,0% sopra il prezzo attuale di mercato. Su 12 analisti, 0 valutano il titolo come acquisto — nel complesso un consenso Vendere.
Simulations Plus Prezzo delle azioni
Simulations Plus Azione e analisi azionaria
Domande frequenti sull'azione Simulations Plus
Simulations Plus Inc is primarily active in the pharmaceutical and biotechnology industries. With a focus on simulation software and consulting services, the company provides cutting-edge solutions for drug discovery and development. Simulations Plus Inc's expertise in modeling and simulation technologies helps pharmaceutical companies optimize their drug formulation and dosage strategies. By leveraging their industry-leading software platforms, Simulations Plus Inc supports the efficient research and development of new therapies, enhancing the overall success and effectiveness of pharmaceutical companies.
The main competitors of Simulations Plus Inc in the market include Certara, Inc and Dassault Systèmes.
The business model of Simulations Plus Inc revolves around providing software and consulting services for pharmaceutical research and development. As a leading provider in the field of drug discovery and development, Simulations Plus Inc aims to enhance the efficiency and effectiveness of the pharmaceutical industry through their innovative solutions. By utilizing computer modeling and simulation software, the company assists in predicting and optimizing drug properties, interactions, and outcomes. This enables scientists and researchers to make informed decisions throughout the drug development process, leading to improved efficacy, safety, and reduced costs. Simulations Plus Inc's comprehensive solutions cater to the needs of pharmaceutical companies, regulatory agencies, and academia worldwide.
Simulations Plus Inc is a leading provider of simulation and modeling software for the pharmaceutical and biotechnology industries. Established in 1996, the company has amassed extensive expertise in the field. Simulations Plus Inc has developed a strong reputation for its cutting-edge technology and innovative solutions, helping pharmaceutical companies optimize drug discovery and development processes. With a focus on increasing efficiency and reducing costs, Simulations Plus Inc has become a trusted partner for numerous organizations worldwide. The company's commitment to excellence has earned them recognition and a loyal customer base. Simulations Plus Inc continues to drive advancements in the industry, delivering impactful software solutions that streamline drug development.
Simulations Plus Inc has achieved significant milestones throughout its history. Some notable accomplishments include the development and release of their industry-leading software solutions, such as GastroPlus™ and DDDPlus™, which have gained widespread recognition and adoption in the pharmaceutical industry. The company has also formed strategic partnerships and collaborations with top pharmaceutical companies, further establishing its presence and credibility in the market. Additionally, Simulations Plus Inc has a strong track record of achieving consistent revenue growth and delivering value to its shareholders. These achievements reflect the company's commitment to innovation, excellence, and meeting the evolving needs of the life sciences industry.
Simulations Plus Inc is primarily present in the United States.
Simulations Plus Inc represents values of innovation, scientific excellence, and customer satisfaction. With a corporate philosophy focused on advancing pharmaceutical research and enhancing drug development, Simulations Plus Inc strives to provide cutting-edge software and consulting services. By combining advanced technologies and domain knowledge, the company facilitates cost-effective and efficient drug discovery and development processes. Simulations Plus Inc is committed to delivering high-quality solutions, fostering collaborative relationships, and continuously improving its products and services.
Gli analisti fissano attualmente un prezzo obiettivo medio di 18,50 USD per l’azione Simulations Plus (mediana: 18,50 USD), pari a +0,0 % rispetto all’ultimo prezzo. Il consenso si basa su 12 giudizi di analisti.
12 analisti valutano attualmente l’azione Simulations Plus: 0 raccomandano l’acquisto, 7 la tenuta e 5 la vendita. Per il 2026 gli analisti si aspettano per Simulations Plus ricavi pari a 81,95 Mio. USD e un utile per azione di 0,86 USD.
Convertita al tasso di cambio attuale, l’azione Simulations Plus quota 16,51 EUR (18,50 USD).
L’azione Simulations Plus (SLP) è quotata su 1 borse, tra cui: NASDAQ (SLP).
Simulations Plus Inc. is a leading company in the field of simulation technology and software development. It provides solutions for researchers and experts in various industries, including biotechnology, pharmaceuticals, agriculture, food technology, and more. The company offers a range of products and tools for data analysis and innovative strategy development to bring new products and applications to the market. Some of its notable products include PK-SIM, MoBi, ADMET Predictor, GastroPlus, DILIsym, and MedChem Studio. Simulations Plus also offers solutions for the agricultural sector, such as Cartagenia, Crop Laptop, and Dose Response Toxicology. The company provides training and support to its customers, aiming to optimize their business processes. Its business model focuses on processing and analyzing large data sets to provide relevant insights and support decision-making processes. Simulations Plus aims to expand into new markets and develop products based on the latest technological advancements.
Il attesa fatturato di Simulations Plus ammonta a 81,95 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Simulations Plus ammonta a 17,49 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Simulations Plus è attualmente 21,39. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Simulations Plus.
Il rapporto prezzo/fatturato (P/S) di Simulations Plus è attualmente 4,56. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Simulations Plus.
Il Quality Score AlleAktien per Simulations Plus è 3/10.
L'ISIN di Simulations Plus è US8292141053. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Simulations Plus è 924294. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Simulations Plus è SLP. Con questo simbolo di borsa vengono negoziate le azioni Simulations Plus in borsa.
Azione Simulations Plus
Gruppo di pari di Simulations Plus
Simulations Plus Ticker
Simulations Plus FIGI
Altre metriche e analisi di Simulations Plus in Deep Dive.
La nostra analisi azionaria dell'azione Simulations Plus include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Simulations Plus. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: